|1.||Barreca, F: 1 article (07/2000)|
|2.||Osburn, B I: 1 article (07/2000)|
|3.||Castrucci, G: 1 article (07/2000)|
|4.||Lo Dico, M: 1 article (07/2000)|
|5.||Frigeri, F: 1 article (07/2000)|
|6.||Salvatori, D: 1 article (07/2000)|
|7.||Ferrari, M: 1 article (07/2000)|
|2.||Communicable Diseases (Infectious Diseases)
01/01/1989 - "The demonstration of the status of paramunity following Baypamun application in cattle provides a concept in the prevention of infectious disease in the practice."
01/01/1989 - "Efficacy of the paramunity inducer Baypamun (PIND-ORF) was evaluated by an IBR challenge trial in cattle, as one model for infectious diseases in bovine. "
02/01/1995 - "The efficacy of an immunomodulator, the Baypamun (Bayer AG), was tested in calves which were subsequently exposed to bovine herpesvirus-1 (BHV-1) infection. "
07/01/2000 - "All six calves were given Baypamun at various times following the exposure to BHV-1 infection and all showed a much reduced reaction with two treated for 4 days developing no clinical disease. "
09/01/1999 - "Since that time, Baypamun is the most commonly used drug for treatment of FeLV infection in Germany and other European countries. "
10/23/1998 - "Therefore, FeLV infection was not influenced by Baypamun treatment."
06/01/1996 - "on post infection day (PID) 2. In addition to the vaccine, two of the four PID 2 vaccinated calves also received a non-specific defence (NSD) inducer (Baypamun, Bayer AG) at the same time as the vaccine. "
|4.||Respiratory Tract Infections (Respiratory Tract Infection)
|5.||Infectious Bovine Rhinotracheitis